GlobeNewswire 05-29 MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder...
GlobeNewswire 05-06 MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Tre...
GlobeNewswire 05-01 MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
GlobeNewswire 04-30 MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
GlobeNewswire 04-29 MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Susp...
GlobeNewswire 04-03 MannKind Repays Certain Debt Obligations
GlobeNewswire 03-26 MannKind Announces CFO Transition
GlobeNewswire 03-11 INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily ...
GlobeNewswire 03-05 MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATT...
GlobeNewswire 03-04 MannKind Corporation Announces Participation at Upcoming Conferences
GlobeNewswire 02-27 MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical ...
GlobeNewswire 02-20 MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on ...
GlobeNewswire 02-15 MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza...
GlobeNewswire 01-02 MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
GlobeNewswire 2023-12-28 MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 2023-11-07 MannKind Corporation Reports 2023 Third Quarter Financial Results
GlobeNewswire 2023-11-06 MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Livi...
GlobeNewswire 2023-10-31 MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 202...
GlobeNewswire 2023-10-30 MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
GlobeNewswire 2023-09-05 MannKind Corporation Announces Participation at Upcoming Conferences
GlobeNewswire 2022-03-28 MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference
GlobeNewswire 2022-03-22 MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit
GlobeNewswire 2022-03-08 MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference
GlobeNewswire 2022-02-24 MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results
GlobeNewswire 2022-02-24 Update on Tyvaso DPI™ New Drug Application